share_log

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

Belite Bio將於2024年5月14日主持網絡直播,討論2024年第一季度的財務業績
GlobeNewswire ·  05/08 08:00

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the first quarter ended March 31, 2024.

聖地亞哥,2024年5月8日(GLOBE NEWSWIRE)——Belite Bio, Inc(納斯達克股票代碼:BLTE)是一家臨床階段的生物製藥藥物開發公司,專注於推進針對醫療需求嚴重未得到滿足的退行性視網膜疾病的新療法。該公司今天宣佈,將於美國東部時間2024年5月14日星期二下午 4:30 舉辦網絡直播,討論該公司的財務業績,並提供截至2024年3月31日的第一季度業務最新情況。

Webcast Information
Date: Tuesday, May 14, 2024
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link:

網絡直播信息
日期:2024 年 5 月 14 日星期二
時間:美國東部時間下午 4:30(太平洋時間下午 1:30)
網絡直播鏈接:

Webcast Link Instructions
You can join the live webcast by visiting the link above or the "Presentations & Events" section of the Company's Investor Relations website at A replay will be available for approximately 90 days after the event.

網絡直播鏈接說明
您可以通過訪問上面的鏈接或公司投資者關係網站的 “演示與活動” 部分來參加網絡直播。活動結束後約90天內將提供重播。

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs such as (i) atrophic age-related macular degeneration (AMD), commonly known as Geographic Atrophy (GA) in advanced dry AMD, and (ii) autosomal recessive Stargardt disease type 1, or STGD1, in addition to specific metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at .

關於 Belite Bio
Belite Bio是一家臨床階段的生物製藥藥物開發公司,專注於推進針對視網膜退行性眼病的新療法,這些疾病的醫療需求尚未得到滿足,例如(i)萎縮性年齡相關性黃斑變性(AMD),在晚期乾性 AMD 中通常稱爲地理萎縮 (GA),以及 (ii) 常染色體隱性遺傳型 1 型斯塔加特病或 STGD1,以及特定的代謝性疾病。欲了解更多信息,請在推特、Instagram、領英、臉書上關注我們或訪問我們。

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

媒體和投資者關係聯繫人:
吳珍妮
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

朱莉·法倫
belite@argotpartners.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論